Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 6/20 | 0.42 |
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
| ▸ | RXRA | P19793 | 5/20 | 0.40 |
| ▸ | RXRG | P48443 | 3/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23883587 | 0.80 | KIF11 (0.53) | RXRBKIF11RXRARXRG | |
| SCHEMBL30129678 | 0.80 | KIF11 (0.53) | RXRBKIF11RXRARXRG | |
| SCHEMBL20595534 | 0.70 | KIF11 (0.53) | RXRBKIF11RXRARXRG | |
| SCHEMBL30467085 | 0.70 | KIF11 (0.53) | RXRBKIF11RXRARXRG | |
| SCHEMBL20825774 | 0.67 | KIF11 (0.68) | RXRBKIF11RXRA | |
| SCHEMBL23883574 | 0.65 | RXRB (0.47) | RXRBKIF11RXRARXRGDHODH | |
| SCHEMBL30129444 | 0.65 | RXRB (0.47) | RXRBKIF11RXRARXRGDHODH | |
| SCHEMBL30129442 | 0.64 | KIF11 (0.53) | RXRBKIF11RXRARXRG | |
| SCHEMBL23883570 | 0.64 | KIF11 (0.53) | RXRBKIF11RXRARXRG | |
| SCHEMBL25883201 | 0.63 | KIF11 (0.70) | RXRBKIF11RXRAJAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129371-A1 | STERICALLY HINDERED PHOSPHINO-UREA SUPPORTED NICKEL (II) OR PALLADIUM (II) CATALYSTS FOR THE COPOLYMERIZATION OF ETHYLENE AND POLAR COMONOMERS | PCNA, NIT2, MCM7 | RXRB 4848/4885KIF11 3734/4885RXRA 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.